Tirzepatide

Mechanism

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is based on the native GIP sequence with modifications to enable GLP-1 receptor cross-reactivity and a C20 fatty diacid moiety for albumin binding and extended half-life. GIP receptor agonism enhances the metabolic signaling effects of GLP-1 pathway activation, including modulation of lipid metabolism and central satiety signaling pathways. The dual mechanism engages complementary metabolic pathways compared to single-receptor agonist approaches.

What the literature has looked at

• Studies have investigated dual incretin receptor pharmacology and metabolic pathway modulation
• Research has examined glycemic signaling in dual-agonist receptor activation models
• Studies have explored effects on hepatic lipid metabolism and steatosis biomarkers
• Research has investigated cardiovascular biomarkers and respiratory signaling pathways

Research context, not a claim about what this compound does. Research Use Only — not for human or animal consumption. 21+.

Cited work

• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216.

  Research investigated the dose-dependent pharmacology of dual GIP/GLP-1 receptor agonism and its effects on metabolic signaling pathways over 72 weeks, comparing dual-receptor engagement to single-agonist approaches.

• Frias JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515.

  Research compared the receptor pharmacology and glycemic signaling effects of dual GIP/GLP-1 agonism versus selective GLP-1 receptor agonism across multiple dose groups.

Properties

cas Number

2023788-19-2

type

Peptide (dual GIP/GLP-1 agonist)